Extended Data Table 5 Total CDK4/6i drug costs per study group with drug prices in the Netherlands derived from both list prices of 2023 (a) and 2019 (b) and the United States (c)

From: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

  1. a. Drug prices in the Netherlands in euros (€), derived from the Dutch list price Z-index of 202320. The total, average, minimum and maximum costs per study group were calculated over all patients with CDK4/6i use at data cut-off date.
  2. b. Drug prices in the Netherlands in euros (€), derived from the Dutch list price Z-index of 201921. The total, average, minimum and maximum costs per study group were calculated over all patients with CDK4/6i use at data cut-off date.
  3. c. Drug prices in the United States (US) in dollars ($), derived from Medicare Part D from 202222. The total, average, minimum and maximum costs per study group were calculated over all patients with CDK4/6i use at data cut-off date.
  4. d. List prices of CDK4/6i for the Netherlands (NL) and the United States (US). These input prices are used to calculate the actual CDK4/6i per patient: the type of CDK4/6i (abemaciclib, palbociclib, ribociclib), dose per administration in milligram (mg), and number of administrations are multiplied with these prices.
Back to article page